How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,414 results for

Skin Conditions in Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

8361. Molecular Mechanisms of Type 2 Diabetes Mellitus

/delay the appearance of vascular disease in patients with type 2 diabetes. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: Pioglitazone Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 39 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Basic Science Official Title: Molecular Mechanisms of Endothelial Dysfunction in Type (...) Molecular Mechanisms of Type 2 Diabetes Mellitus Molecular Mechanisms of Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Molecular Mechanisms of Type 2 Diabetes Mellitus The safety

2008 Clinical Trials

8362. Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus

Last Update Posted : May 21, 2012 Sponsor: Takeda Information provided by (Responsible Party): Takeda Study Details Study Description Go to Brief Summary: The purpose of this study is to determine the efficacy and safety of SYR-619, once daily (QD), in subjects with type 2 diabetes mellitus who have not achieved glycemic control with diet and exercise, or by taking metformin. Condition or disease Intervention/treatment Phase Diabetes Mellitus Drug: SYR-619 Drug: Placebo Drug: Alogliptin Phase 2 (...) Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2008 Clinical Trials

8363. Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin

Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study (...) Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S

2008 Clinical Trials

8364. Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus

Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus (ASTRIDE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00787605 Recruitment Status : Completed First Posted : November 7, 2008 Results

2008 Clinical Trials

8365. Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.

: September 30, 2008 Last Update Posted : February 28, 2012 Sponsor: Takeda Information provided by (Responsible Party): Takeda Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the safety and efficacy of TAK-559, once daily (QD), taken in combination with metformin in treating subjects with type 2 diabetes mellitus Condition or disease Intervention/treatment Phase Diabetes Mellitus Drug: TAK-559 and metformin Drug: Metformin Phase 3 Detailed Description (...) by the investigator before Randomization. Exclusion Criteria: Diagnosed with type 1 diabetes mellitus, hemochromatosis, or had a history of ketoacidosis. Had any condition known to invalidate glycosylated hemoglobin results (eg, hemolytic states or hemoglobinopathies). Took any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may have interfered with evaluation of the study medication, including: Insulin Oral antidiabetics including sulfonylureas and alpha

2008 Clinical Trials

8366. Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

, 2012 Sponsor: Takeda Information provided by (Responsible Party): Takeda Study Details Study Description Go to Brief Summary: The purpose of this study was to determine the safety and efficacy of TAK-559, once daily (QD), in treating subjects with type 2 diabetes mellitus. Condition or disease Intervention/treatment Phase Diabetes Mellitus Drug: TAK-559 Drug: Placebo Phase 3 Detailed Description: Insulin is a primary regulator of blood glucose concentrations. A subnormal response to circulating (...) fasting clinical laboratory evaluations within the normal reference range for the testing laboratory, or if not, the results must be deemed not clinically significant by the investigator prior to Randomization. Females were post menopausal, surgically sterile, or using adequate contraception. Exclusion Criteria: Had been diagnosed with type 1 diabetes mellitus, hemochromatosis, or has a history of ketoacidosis. Had any condition known to invalidate glycosylated hemoglobin results (eg, hemolytic states

2008 Clinical Trials

8367. Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

): Takeda Study Details Study Description Go to Brief Summary: The purpose of this study was to determine the safety of TAK-559, once daily (QD), in treating subjects receiving a stable dose of insulin to control type 2 diabetes mellitus. Condition or disease Intervention/treatment Phase Diabetes Mellitus Drug: TAK-559 and insulin Drug: Insulin Phase 3 Detailed Description: Insulin is a primary regulator of blood glucose concentrations. A subnormal response to circulating insulin levels at target (...) Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study of TAK-559

2008 Clinical Trials

8368. Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Study Description Go to Brief Summary: The purpose of this study was to determine the safety and efficacy of TAK-559, once daily (QD), in Type 2 Diabetes subjects. Condition or disease Intervention/treatment Phase Diabetes Mellitus Drug: TAK-559 Drug: Placebo Phase 3 Detailed Description: Insulin is a primary regulator of blood glucose concentrations. A subnormal response to circulating insulin levels at target tissues leads to a decrease in insulin-mediated glucose uptake. Insulin resistance (...) , surgically sterile, or using adequate contraception. Exclusion Criteria: Was diagnosed with type 1 diabetes mellitus, hemochromatosis, or has a history of ketoacidosis. Had any condition known to invalidate glycosylated hemoglobin results (eg, hemolytic states, hemoglobinopathies). Was required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including

2008 Clinical Trials

8369. Impact of GBS on CVD in Type 2 Diabetes Mellitus

this surgery. We will determine protein expression profiles of inflammation-related adipokines in the subcutaneous and intra-abdominal adipose tissues of morbidly obese subjects with T2DM before and after surgically induced weight loss. Condition or disease Intervention/treatment Phase Obesity Type 2 Diabetes Mellitus Other: Diabetes Support and Education Procedure: gastric bypass surgery Other: Tissue Control Group Not Applicable Detailed Description: Patients with type 2 diabetes mellitus (T2DM) are more (...) the abdominal surgery we would like to take 5 ml blood from the IV line and small pea-sized samples of the fat tissue just under the skin and around the stomach area. These samples will be stored so that we can compare these tissue with other patients. Outcome Measures Go to Primary Outcome Measures : To determine whether surgically induced weight loss decreases the risk of CVD in morbidly obese subjects with Type 2 Diabetes Mellitus (T2DM) [ Time Frame: 0, 6, 12 months ] Patients with T2DM who undergo

2008 Clinical Trials

8370. Bone Marrow Mononuclear Cell and Hyperbaric Oxygen Therapy in Diabetes Mellitus

were tested for CD34+ flow cytometry and whole blood cell count. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: BM-MNC+HOT Drug: BM-MNC Device: HOT Drug: SMT Phase 1 Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 82 participants Allocation: Randomized Intervention Model: Factorial Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Autologous Bone Marrow (...) Bone Marrow Mononuclear Cell and Hyperbaric Oxygen Therapy in Diabetes Mellitus Bone Marrow Mononuclear Cell and Hyperbaric Oxygen Therapy in Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2008 Clinical Trials

8371. Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus

the excretion of protein in the urine is being measured as a secondary endpoint. Condition or disease Intervention/treatment Phase Diabetes Mellitus Drug: FG-3019 Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 20 participants Allocation: Non-Randomized Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Phase 1 Study of the Safety, Pharmacokinetics, and Biologic Activity of Escalating Doses of FG-3019 (...) Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2005 Clinical Trials

8372. Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

versus treatment with premix insulin. Condition or disease Intervention/treatment Phase Diabetes Mellitus Drug: insulin glargine Drug: insulin glulisine Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 582 participants Allocation: Randomized Intervention Model: Crossover Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Insulin Glargine Plus Insulin Glulisine MDI Versus Premix Insulin (...) Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2) Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record

2005 Clinical Trials

8373. Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin

. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 2 Drug: insulin glulisine Drug: insulin glargine Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 345 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: APIDRA® (Insulin Glulisine) Administered Premeal vs Postmeal in Adult Subjects With Type 2 Diabetes Mellitus (...) Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved

2005 Clinical Trials

8374. Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus When Failing on OADs

17, 2010 Last Update Posted : December 8, 2014 Sponsor: Novo Nordisk A/S Information provided by (Responsible Party): Novo Nordisk A/S Study Details Study Description Go to Brief Summary: This trial is conducted in Europe. This is a clinical trial investigating the effectiveness and the safety of using biphasic insulin aspart 30 both for initiation and intensification of insulin treatment in type 2 diabetes. Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug (...) Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus When Failing on OADs Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus When Failing on OADs - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2007 Clinical Trials

8375. The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

or liraglutide 1.8 mg/day. Liraglutide will be initiated at a dose of 0.6 mg/day, and increased to 1.2 mg/day or 1.8 mg/day in weekly intervals. Subjects receiving liraglutide 1.2 mg/day or 1.8 mg/day at the end of week 52 after randomisation will continue the treatment at unchanged dose and dosing regimen. Trial completion is planned for June 2010. Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug: liraglutide Drug: sitagliptin Drug: metformin Phase 3 Study Design Go (...) The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved

2008 Clinical Trials

8376. Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus

for details. ClinicalTrials.gov Identifier: NCT00552227 Recruitment Status : Completed First Posted : November 1, 2007 Last Update Posted : July 26, 2016 Sponsor: Chromaderm, Inc. Information provided by: Chromaderm, Inc. Study Details Study Description Go to Brief Summary: The purpose of this study is to determine whether ruboxistaurin can reduce blood vessel inflammation associated with diabetes. Condition or disease Intervention/treatment Phase Diabetes Mellitus Drug: ruboxistaurin Other: placebo Phase (...) Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved

2007 Clinical Trials

8377. Single-dose, Dose-escalation Study of Safety, PK, and Preliminary Efficacy of XOMA 052 in Type 2 Diabetes Mellitus

10, 2007 Last Update Posted : May 4, 2010 Sponsor: XOMA (US) LLC Information provided by: XOMA (US) LLC Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the safety, pharmacokinetics (PK) and preliminary efficacy of XOMA 052 in subjects with active Type 2 Diabetes Mellitus (T2D). IV administration of XOMA 052 is likely to improve glycemic control in subjects with T2D by blocking certain receptors. Condition or disease Intervention/treatment Phase Type 2 (...) Single-dose, Dose-escalation Study of Safety, PK, and Preliminary Efficacy of XOMA 052 in Type 2 Diabetes Mellitus Single-dose, Dose-escalation Study of Safety, PK, and Preliminary Efficacy of XOMA 052 in Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2007 Clinical Trials

8378. Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus

transplantation Using a steroid-free immunosuppression regimen Transplanting the best combination of donor and recipient possible after HLA screening and final crossmatching Condition or disease Intervention/treatment Phase Islets of Langerhans Transplantation Diabetes Mellitus, Type 1 Drug: Islets of Langerhans Phase 1 Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 30 participants Intervention Model: Single Group Assignment (...) Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2007 Clinical Trials

8379. The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus

: March 8, 2017 Sponsor: Novo Nordisk A/S Information provided by (Responsible Party): Novo Nordisk A/S Study Details Study Description Go to Brief Summary: This trial is conducted in the United States of America (USA). The purpose of the trial is to assess the effect of liraglutide on forearm blood flow in subjects with type 2 diabetes who are on diet and lifestyle changes or treated with metformin alone. Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug (...) The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2008 Clinical Trials

8380. The Impact of Pancreatic Islet Cell Allotransplantation on Cognitive Function in Type 1 Diabetes Mellitus

The Impact of Pancreatic Islet Cell Allotransplantation on Cognitive Function in Type 1 Diabetes Mellitus The Impact of Pancreatic Islet Cell Allotransplantation on Cognitive Function in Type 1 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. The Impact of Pancreatic Islet Cell Allotransplantation on Cognitive Function in Type 1 Diabetes Mellitus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00590876 Recruitment Status : Completed First Posted : January 11, 2008 Last Update Posted

2007 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>